BMO Capital Markets reiterated its Outperform rating on Eli Lilly and Company (NYSE:LLY), setting a price target of $900 ...

Eli Lilly recently announced the impressive results of its SURMOUNT-5 trial, highlighting Zepbound's efficacy over Wegovy in weight management. This promising development was disclosed alongside ...

Even though Eli Lilly and Company (NYSE:LLY) posted strong earnings, investors appeared to be underwhelmed. Our analysis says that investors should be optimistic, as the strong profit is built on ...

Investing.com-- Eli Lilly’s (NYSE: LLY) Zepbound demonstrated significantly greater weight loss than Novo Nordisk ’s (CSE: NOVOb) Wegovy in a head-to-head clinical trial, the company said on ...

Matthew Herper covers medical innovation — both its promise and its perils. A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap ...

Eli Lilly’s total deal value with Rznomics could exceed $1.3 billion, plus royalties. Rznomics will lead early-stage research; Lilly to handle development and sales. Get stock picks, daily ...

While many pharma and biotech companies developing drugs to treat Alzheimer's disease are targeting amyloid beta plaque, Eli Lilly (NYSE:LLY) is looking at other targets as well. The drugmaker's ...

Under the agreement, Alchemab will advance ATLX-1282, which has already completed preclinical development through early Phase 1 clinical trials, before Eli Lilly (NYSE:LLY) takes over its ...

From late 2020 to the summer of 2024, Eli Lilly & Co. (NYSE ... However, we will walk you through our assumptions and provide the key drivers we see propelling Lilly’s stock in the future.

Eli Lilly & Co. said Tuesday it’s cutting the price of single-dose vials of its Zepbound treatment for diabetes and obesity for patients who have to pay for the drug themselves. It said it will ...

Eli Lilly and Purdue University are changing how groundbreaking research can be funded as universities and labs across the country grapple with sudden federal funding cuts to vital research.

Eli Lilly's potential Houston expansion could bring thousands of jobs and billions of dollars in investment to the area. Here's where the plant might be built ...